This module uses fundamental data of PYC Therapeutics to approximate its Piotroski F score. PYC Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of PYC Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about PYC Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
PYC
Piotroski F Score
Capital Expenditures
Total Cash From Operating Activities
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Change In Cash
Free Cash Flow
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Net Income
Change To Account Receivables
Stock Based Compensation
Change In Working Capital
Total Cashflows From Investing Activities
Change To Operating Activities
Change To Netincome
Change To Liabilities
Change To Inventory
Investments
Other Cashflows From Investing Activities
Net Borrowings
Issuance Of Capital Stock
Dividends Paid
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Accounts Payable
Cash
Net Receivables
Total Liab
Intangible Assets
Common Stock
Property Plant Equipment
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Long Term Debt Total
Short Term Debt
Other Liab
Non Current Liabilities Total
Non Currrent Assets Other
Inventory
Net Tangible Assets
Long Term Debt Total
Net Invested Capital
Cash And Equivalents
Net Working Capital
Capital Stock
Capital Lease Obligations
Interest Expense
Cost Of Revenue
Depreciation And Amortization
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling And Marketing Expenses
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Minority Interest
Probability Of Bankruptcy
Long Term Debt Total is likely to gain to about 315.8 K in 2024, despite the fact that Net Debt is likely to grow to (62.5 M).
At this time, it appears that PYC Therapeutics' Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to PYC Therapeutics is to make sure PYC is not a subject of accounting manipulations and runs a healthy internal audit department. So, if PYC Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if PYC Therapeutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between PYC Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards PYC Therapeutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Net Debt
(62.47 Million)
At this time, PYC Therapeutics' Net Debt is comparatively stable compared to the past year.
About PYC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PYC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PYC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PYC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.